| NCT03382431 |
A Study of PC786 to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of Multiple Doses in an RSV Challenge Study |
https://ClinicalTrials.gov/show/NCT03382431 |
Completed |
Pulmocide Ltd |
2018-05-09 |
| NCT03379675 |
A Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Participants Infected With Respiratory Syncytial Virus |
https://ClinicalTrials.gov/show/NCT03379675 |
Completed |
Janssen Research & Development, LLC |
2019-11-27 |
| NCT03334695 |
An Exploratory Study to Evaluate the Prophylactic Efficacy of a Single Immunization of Ad26.RSV.preF Against Respiratory Syncytial Virus Infection in a Virus Challenge Model in Healthy 18 to 50 Year-old Adults |
https://ClinicalTrials.gov/show/NCT03334695 |
Completed |
Janssen Vaccines & Prevention B.V. |
2018-07-10 |
| NCT03332459 |
A Long-term Follow-up Study to Evaluate the Impact of Lumicitabine on the Incidence of Asthma and/or Wheezing in Infants and Children With a History of Respiratory Syncytial Virus Infection |
https://ClinicalTrials.gov/show/NCT03332459 |
Completed |
Janssen Research & Development, LLC |
2020-04-13 |
| NCT03258502 |
Safety, Pharmacokinetics and Antiviral Activity of RV521 Against RSV |
https://ClinicalTrials.gov/show/NCT03258502 |
Completed |
ReViral Ltd |
2017-10-31 |
| NCT03227029 |
Evaluating the Infectivity, Safety, and Immunogenicity of the Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants 6 to 24 Months of Age |
https://ClinicalTrials.gov/show/NCT03227029 |
Active, not recruiting |
National Institute of Allergy and Infectious Diseases (NIAID) |
2019-12-19 |
| NCT03171142 |
Effect of Heliox on RSV Bronchiolitis |
https://ClinicalTrials.gov/show/NCT03171142 |
Completed |
Mansoura University Children Hospital |
2016-08-01 |
| NCT03102034 |
Evaluating the Infectivity, Safety, and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants 6 to 24 Months of Age |
https://ClinicalTrials.gov/show/NCT03102034 |
Completed |
National Institute of Allergy and Infectious Diseases (NIAID) |
2018-05-25 |
| NCT03099291 |
Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants and Children 6 to 24 Months of Age |
https://ClinicalTrials.gov/show/NCT03099291 |
Completed |
National Institute of Allergy and Infectious Diseases (NIAID) |
2018-04-30 |
| NCT03062917 |
Nasal and Bronchial Absorption Sampling in RSV Bronchiolitis |
https://ClinicalTrials.gov/show/NCT03062917 |
Completed |
Imperial College Healthcare NHS Trust |
2018-06-30 |
| NCT02956837 |
A Study to Rank Different Dosages of Antigen of GlaxoSmithKline (GSK) Biologicals’ Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A), Based on Their Immune Response and Safety, When Administered to Healthy Adult Women |
https://ClinicalTrials.gov/show/NCT02956837 |
Completed |
GlaxoSmithKline |
2017-08-30 |
| NCT02952339 |
Evaluating the Infectivity, Safety, and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants and Children 6 to 24 Months of Age |
https://ClinicalTrials.gov/show/NCT02952339 |
Completed |
National Institute of Allergy and Infectious Diseases (NIAID) |
2017-07-31 |
| NCT02927873 |
RSV Investigational Vaccine in RSV-seropositive Infants Aged 12 to 23 Months |
https://ClinicalTrials.gov/show/NCT02927873 |
Active, not recruiting |
GlaxoSmithKline |
2019-02-19 |
| NCT02878330 |
A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Preterm Infants. |
https://ClinicalTrials.gov/show/NCT02878330 |
Completed |
MedImmune LLC |
2018-07-17 |
| NCT02794870 |
Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants 6 to 24 Months of Age |
https://ClinicalTrials.gov/show/NCT02794870 |
Completed |
National Institute of Allergy and Infectious Diseases (NIAID) |
2017-07-07 |
| NCT02755948 |
A Study of Protective Immunity Against RSV and Influenza in Experimental Human Challenge of Volunteers |
https://ClinicalTrials.gov/show/NCT02755948 |
Recruiting |
Imperial College London |
2020-09-30 |
| NCT02753413 |
Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals’ Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A) in Healthy Women |
https://ClinicalTrials.gov/show/NCT02753413 |
Completed |
GlaxoSmithKline |
2016-06-28 |
| NCT02673476 |
A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus |
https://ClinicalTrials.gov/show/NCT02673476 |
Completed |
Alios Biopharma Inc. |
2016-10-31 |
| NCT02654171 |
Viral Inhibition in Children for Treatment of RSV |
https://ClinicalTrials.gov/show/NCT02654171 |
Completed |
Ark Biosciences Inc. |
2019-03-31 |
| NCT02624947 |
A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization |
https://ClinicalTrials.gov/show/NCT02624947 |
Completed |
Novavax |
2019-03-31 |
| NCT02601612 |
Safety and Immunogenicity of the RSV D46cpΔM2-2 Vaccine in RSV-Seropositive Children and RSV-Seronegative Infants and Children |
https://ClinicalTrials.gov/show/NCT02601612 |
Completed |
National Institute of Allergy and Infectious Diseases (NIAID) |
2018-04-26 |
| NCT03387137 |
Evaluating the Infectivity, Safety, and Immunogenicity of a Respiratory Syncytial Virus Vaccine (RSV 6120/∆NS2/1030s) in RSV-Seropositive Children and RSV-Seronegative Infants and Children |
https://ClinicalTrials.gov/show/NCT03387137 |
Active, not recruiting |
National Institute of Allergy and Infectious Diseases (NIAID) |
2019-11-22 |
| NCT02478333 |
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ALS-008176 in Healthy Japanese Adult Participants |
https://ClinicalTrials.gov/show/NCT02478333 |
Completed |
Janssen Pharmaceutical K.K. |
2015-07-31 |
| NCT02419391 |
Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA BN® RSV Vaccine |
https://ClinicalTrials.gov/show/NCT02419391 |
Completed |
Bavarian Nordic |
2015-12-31 |
| NCT02387606 |
Study to Evaluate Antiviral Activity, Safety, and Pharmacokinetics of Repeated Doses of Orally Administered JNJ 53718678 Against Respiratory Syncytial Virus Infection. |
https://ClinicalTrials.gov/show/NCT02387606 |
Completed |
Janssen Sciences Ireland UC |
2015-09-21 |
| NCT02360475 |
Safety, Reactogenicity and Immunogenicity Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals’ Investigational RSV Vaccine (GSK3003891A), in Healthy Women |
https://ClinicalTrials.gov/show/NCT02360475 |
Completed |
GlaxoSmithKline |
2015-07-02 |
| NCT02325791 |
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants |
https://ClinicalTrials.gov/show/NCT02325791 |
Completed |
Regeneron Pharmaceuticals |
2017-07-05 |
| NCT02309320 |
A Multicentre Study in Otherwise Healthy Infants and Toddlers Hospitalised For and Diagnosed With RSV Lower Respiratory Tract Infection to Evaluate the Safety, Tolerability, and Clinical Activity of ALX-0171 |
https://ClinicalTrials.gov/show/NCT02309320 |
Completed |
Ablynx |
2016-02-29 |
| NCT02297594 |
Safety, Tolerability and PK Study of AK0529 in Healthy Human |
https://ClinicalTrials.gov/show/NCT02297594 |
Completed |
Ark Biosciences Inc. |
2015-06-30 |
| NCT02254421 |
Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract |
https://ClinicalTrials.gov/show/NCT02254421 |
Completed |
Gilead Sciences |
2017-04-17 |
| NCT02247726 |
RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women. |
https://ClinicalTrials.gov/show/NCT02247726 |
Completed |
Novavax |
2016-07-31 |
| NCT02237209 |
Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children |
https://ClinicalTrials.gov/show/NCT02237209 |
Completed |
National Institute of Allergy and Infectious Diseases (NIAID) |
2015-04-30 |
| NCT02231671 |
A Phase 1, Open-Label Study of the Absorption, Metabolism, Excretion and Absolute Bioavailability of ALS-008176 |
https://ClinicalTrials.gov/show/NCT02231671 |
Completed |
Alios Biopharma Inc. |
2014-09-30 |
| NCT02202356 |
A Study of ALS-008176 in Infants Hospitalized With RSV |
https://ClinicalTrials.gov/show/NCT02202356 |
Completed |
Alios Biopharma Inc. |
2018-02-15 |
| NCT02201303 |
Evaluation of Danirixin (GSK1325756) Inhibition of CD11b Cell Surface Expression |
https://ClinicalTrials.gov/show/NCT02201303 |
Completed |
GlaxoSmithKline |
2015-07-02 |
| NCT03384823 |
A Study of EDP-938 in Healthy Subjects |
https://ClinicalTrials.gov/show/NCT03384823 |
Completed |
Enanta Pharmaceuticals |
2018-07-03 |
| NCT02135614 |
Efficacy, Pharmacokinetics, and Safety of Presatovir in Hospitalized Adults With Respiratory Syncytial Virus (RSV) Infection |
https://ClinicalTrials.gov/show/NCT02135614 |
Completed |
Gilead Sciences |
2017-03-27 |
| NCT02114268 |
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897 in Healthy Adults |
https://ClinicalTrials.gov/show/NCT02114268 |
Completed |
MedImmune LLC |
2015-06-30 |
| NCT02094365 |
A Phase 2a Study to Evaluate ALS-008176 in the Virus Challenge Model |
https://ClinicalTrials.gov/show/NCT02094365 |
Completed |
Alios Biopharma Inc. |
2014-06-30 |
| NCT01290419 |
Safety Study of Respiratory Syncytial Virus (RSV)-Fusion (F) Protein Particle Vaccine |
https://ClinicalTrials.gov/show/NCT01290419 |
Completed |
Novavax |
2011-12-31 |
| NCT02040831 |
Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children |
https://ClinicalTrials.gov/show/NCT02040831 |
Completed |
National Institute of Allergy and Infectious Diseases (NIAID) |
2015-04-30 |
| NCT03959488 |
A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children |
https://ClinicalTrials.gov/show/NCT03959488 |
Recruiting |
MedImmune LLC |
2022-12-02 |
| NCT01960686 |
RSV F Dose-Ranging Study in Women |
https://ClinicalTrials.gov/show/NCT01960686 |
Completed |
Novavax |
2014-04-30 |
| NCT01909843 |
ALX-0171 Safety Study in Adults With Hyperresponsive Airways |
https://ClinicalTrials.gov/show/NCT01909843 |
Completed |
Ablynx |
2013-12-31 |
| NCT01906164 |
Study of Single and Multiple Doses of ALS-008176 in Healthy Volunteers |
https://ClinicalTrials.gov/show/NCT01906164 |
Completed |
Alios Biopharma Inc. |
2013-11-30 |
| NCT01905215 |
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals’ Investigational Respiratory Syncytial Virus (RSV) Vaccines |
https://ClinicalTrials.gov/show/NCT01905215 |
Completed |
GlaxoSmithKline |
2014-04-09 |
| NCT01893554 |
Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in Infants and Children |
https://ClinicalTrials.gov/show/NCT01893554 |
Recruiting |
National Institute of Allergy and Infectious Diseases (NIAID) |
2020-12-31 |
| NCT01875926 |
ALX-0171 Phase I Pharmacokinetic Study in Healthy Male Volunteers |
https://ClinicalTrials.gov/show/NCT01875926 |
Completed |
Ablynx |
2013-10-31 |
| NCT01852266 |
Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children |
https://ClinicalTrials.gov/show/NCT01852266 |
Completed |
National Institute of Allergy and Infectious Diseases (NIAID) |
2015-07-31 |
| NCT01805921 |
RSV001 - A New Vaccine to Prevent Severe Viral Chest Infections. |
https://ClinicalTrials.gov/show/NCT01805921 |
Completed |
ReiThera Srl |
2015-08-31 |
| NCT01801293 |
A Phase 1 Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of GS-5806 |
https://ClinicalTrials.gov/show/NCT01801293 |
Completed |
Gilead Sciences |
2013-04-30 |
| NCT01756482 |
Safety and Efficacy Study of GS-5806 in Healthy Volunteers Infected With Respiratory Syncytial Virus (RSV) |
https://ClinicalTrials.gov/show/NCT01756482 |
Completed |
Gilead Sciences |
2013-06-30 |
| NCT01502072 |
Respiratory Syncytial Virus - RSV Protocol |
https://ClinicalTrials.gov/show/NCT01502072 |
Completed |
M.D. Anderson Cancer Center |
2020-02-01 |
| NCT01483911 |
ALX-0171 Phase I Study, Evaluating Single Ascending Dose and Multiple Dose in Healthy Male Volunteers |
https://ClinicalTrials.gov/show/NCT01483911 |
Completed |
Ablynx |
2012-05-31 |
| NCT01466062 |
Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions |
https://ClinicalTrials.gov/show/NCT01466062 |
Completed |
AbbVie |
2012-04-30 |
| NCT01459198 |
Evaluating the Safety and Immune Response to a Respiratory Syncytial Virus (RSV) Vaccine in Adults, RSV-Seropositive Children, and RSV-Seronegative Infants and Children |
https://ClinicalTrials.gov/show/NCT01459198 |
Completed |
National Institute of Allergy and Infectious Diseases (NIAID) |
2015-06-30 |
| NCT01355016 |
A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of MDT-637 in Healthy Volunteers |
https://ClinicalTrials.gov/show/NCT01355016 |
Completed |
MicroDose Therapeutx, Inc |
2011-11-30 |
| NCT01349543 |
The Development of a Human Model of Respiratory Syncytial Virus Infection |
https://ClinicalTrials.gov/show/NCT01349543 |
Completed |
Imperial College London |
2013-10-31 |
| NCT04267822 |
Study of RV521 in the Treatment of Adult Subjects Who Have Undergone HCT With an URTI With RSV |
https://ClinicalTrials.gov/show/NCT04267822 |
Recruiting |
ReViral Ltd |
2022-06-30 |
| NCT04227210 |
Safety and Immune Response to an Investigational Vaccine Against Respiratory Syncytial Virus in Healthy Adults |
https://ClinicalTrials.gov/show/NCT04227210 |
Active, not recruiting |
Meissa Vaccines, Inc. |
2020-07-31 |
| NCT04126213 |
Study of Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline’s (GSK)Respiratory Syncytial Virus (RSV)Maternal Unadjuvanted Vaccine in Healthy Pregnant Women (Aged 18 to 40 Years) and Their Infants |
https://ClinicalTrials.gov/show/NCT04126213 |
Active, not recruiting |
GlaxoSmithKline |
2020-07-07 |
| NCT04090658 |
A Study to Test GlaxoSmithKline’s (GSK) Respiratory Syncytial Virus RSV Candidate Vaccine’s Safety and Immune Response in Japanese Older Adults |
https://ClinicalTrials.gov/show/NCT04090658 |
Active, not recruiting |
GlaxoSmithKline |
2020-01-10 |
| NCT04065698 |
Pharmacokinetics and Safety of RV521 Formulations |
https://ClinicalTrials.gov/show/NCT04065698 |
Completed |
ReViral Ltd |
2019-09-02 |
| NCT04056611 |
Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV) |
https://ClinicalTrials.gov/show/NCT04056611 |
Recruiting |
Janssen Sciences Ireland UC |
2022-08-15 |
| NCT03979313 |
A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Late Preterm and Term Infants |
https://ClinicalTrials.gov/show/NCT03979313 |
Recruiting |
MedImmune LLC |
2022-05-02 |
| NCT03919591 |
RSV Study in Adults 60 to 75 Years of Age |
https://ClinicalTrials.gov/show/NCT03919591 |
Completed |
Hvivo |
2019-07-11 |
| NCT03814590 |
A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithKline (GSK) Biologicals’ Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3844766A) in Older Adults |
https://ClinicalTrials.gov/show/NCT03814590 |
Active, not recruiting |
GlaxoSmithKline |
2019-12-12 |
| NCT03782662 |
Drug Interaction Study With RV521 in Healthy Volunteer Subjects |
https://ClinicalTrials.gov/show/NCT03782662 |
Completed |
ReViral Ltd |
2019-03-17 |
| NCT03755778 |
Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects |
https://ClinicalTrials.gov/show/NCT03755778 |
Completed |
Enanta Pharmaceuticals |
2019-01-21 |
| NCT03750383 |
Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult Subjects |
https://ClinicalTrials.gov/show/NCT03750383 |
Completed |
Enanta Pharmaceuticals |
2018-11-17 |
| NCT03728413 |
The Impact of Age on Adaptive Immunity in Adults Infected With Respiratory Syncytial Virus |
https://ClinicalTrials.gov/show/NCT03728413 |
Recruiting |
Imperial College London |
2023-09-28 |
| NCT03699202 |
Anti-RSV Study in Chinese Patients (ASCENT) |
https://ClinicalTrials.gov/show/NCT03699202 |
Recruiting |
Ark Biosciences Inc. |
2020-01-31 |
| NCT03691623 |
A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge Model |
https://ClinicalTrials.gov/show/NCT03691623 |
Completed |
Enanta Pharmaceuticals |
2019-09-30 |
| NCT03674177 |
A Study to Evaluate Different Dose Levels of GlaxoSmithKline (GSK) Biologicals’ Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3888550A), Based on the Vaccine Safety and the Antibodies (Body Defences) Produced Following Vaccine Administration, When Given to Healthy Non-pregnant Women |
https://ClinicalTrials.gov/show/NCT03674177 |
Completed |
GlaxoSmithKline |
2019-04-16 |
| NCT03636906 |
Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV |
https://ClinicalTrials.gov/show/NCT03636906 |
Active, not recruiting |
GlaxoSmithKline |
2020-01-16 |
| NCT03629145 |
Music Therapy With Intubated and Sedated Pediatric Patients |
https://ClinicalTrials.gov/show/NCT03629145 |
Completed |
Children’s Healthcare of Atlanta |
2019-03-01 |
| NCT03624790 |
Inpatient Challenge Study of rRSV A/Maryland/001/11, a Human Respiratory Syncytial Virus Challenge Strain, Administered to Healthy Adult Volunteers |
https://ClinicalTrials.gov/show/NCT03624790 |
Active, not recruiting |
National Institute of Allergy and Infectious Diseases (NIAID) |
2020-12-31 |
| NCT03614676 |
A Study of Outcomes and Events of Interest in Pregnant Women, Neonates and Infants and of RSV Surveillance |
https://ClinicalTrials.gov/show/NCT03614676 |
Active, not recruiting |
GlaxoSmithKline |
2021-08-04 |
| NCT03596801 |
Evaluating the Infectivity, Safety and Immunogenicity of Respiratory Syncytial Virus Vaccines, RSV 6120/∆NS1 and RSV 6120/F1/G2/∆NS1, in RSV-Seropositive Children and RSV-Seronegative Infants and Children |
https://ClinicalTrials.gov/show/NCT03596801 |
Recruiting |
National Institute of Allergy and Infectious Diseases (NIAID) |
2020-04-30 |
| NCT03473002 |
A Safety and Immunogenicity Study of Intranasal Sendai Virus Vectored Respiratory Syncytial Virus (SeVRSV) Vaccine in Healthy Adults |
https://ClinicalTrials.gov/show/NCT03473002 |
Completed |
National Institute of Allergy and Infectious Diseases (NIAID) |
2019-02-14 |
| NCT03422237 |
Evaluating the Infectivity, Safety, and Immunogenicity of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants and Children 6 to 24 Months of Age |
https://ClinicalTrials.gov/show/NCT03422237 |
Active, not recruiting |
National Institute of Allergy and Infectious Diseases (NIAID) |
2020-09-20 |
| NCT01230645 |
RV568 - Viral Challenge With RSV |
https://ClinicalTrials.gov/show/NCT01230645 |
Completed |
Respivert Ltd |
2010-12-31 |
| NCT01065935 |
Phase 2b Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV) |
https://ClinicalTrials.gov/show/NCT01065935 |
Completed |
Alnylam Pharmaceuticals |
2012-04-30 |
| NCT01006629 |
Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children |
https://ClinicalTrials.gov/show/NCT01006629 |
Completed |
Abbott |
2010-04-30 |
| NCT04444284 |
Study of the Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seropositive Children |
https://ClinicalTrials.gov/show/NCT04444284 |
Recruiting |
Meissa Vaccines, Inc. |
2021-03-31 |
| NCT02873286 |
RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults |
https://ClinicalTrials.gov/show/NCT02873286 |
Completed |
Bavarian Nordic |
2018-12-31 |
| NCT04138056 |
A Study of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Diphtheria, Pertussis and Tetanus (Tdap) Viruses to Healthy Non-Pregnant Women |
https://ClinicalTrials.gov/show/NCT04138056 |
Active, not recruiting |
GlaxoSmithKline |
2020-02-25 |
| NCT00658086 |
Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV) |
https://ClinicalTrials.gov/show/NCT00658086 |
Completed |
Alnylam Pharmaceuticals |
2009-04-30 |
| NCT00504907 |
Safety Study of Oral BTA9881 to Treat RSV Infection |
https://ClinicalTrials.gov/show/NCT00504907 |
Completed |
Vaxart |
2008-12-31 |
| NCT00496821 |
Intranasal ALN-RSV01 Administered to Adult Volunteers Experimentally Inoculated With Respiratory Syncytial Virus |
https://ClinicalTrials.gov/show/NCT00496821 |
Completed |
Alnylam Pharmaceuticals |
NA |
| NCT00493285 |
Safety and Tolerability Study to Evaluate MEDI-534 in Children 6 to < 24 Months of Age |
https://ClinicalTrials.gov/show/NCT00493285 |
Completed |
MedImmune LLC |
2009-11-30 |
| NCT00435994 |
Assessment of Airway Obstruction in Infants With Lower Respiratory Infections |
https://ClinicalTrials.gov/show/NCT00435994 |
Completed |
Indiana University |
2009-03-31 |
| NCT00316264 |
Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) Season |
https://ClinicalTrials.gov/show/NCT00316264 |
Completed |
MedImmune LLC |
2007-02-28 |
| NCT00232635 |
A Study of the Safety and Efficacy of A-60444 in Adults With Respiratory Syncytial Virus (RSV) Infection Following HSCT |
https://ClinicalTrials.gov/show/NCT00232635 |
Completed |
Arrow Therapeutics |
2006-07-31 |
| NCT00192504 |
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a Single Intravenous Dose of MEDI-524, a Humanized Enhanced Potency Monoclonal Antibody to Respiratory Syncytial Virus (RSV), in Otherwise Healthy Children Hospitalized With RSV Infection |
https://ClinicalTrials.gov/show/NCT00192504 |
Completed |
MedImmune LLC |
NA |
| NCT00192478 |
Open-Label, Dose-Escalation Study of 2 to 5 IM Doses of MEDI-524 at 3 mg/kg or 15 mg/kg; Children to be Followed for 90 Days After Their Last Dose of MEDI-524 |
https://ClinicalTrials.gov/show/NCT00192478 |
Completed |
MedImmune LLC |
2006-05-31 |
| NCT00192465 |
Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-524 in Healthy Adults |
https://ClinicalTrials.gov/show/NCT00192465 |
Completed |
MedImmune LLC |
2004-04-30 |
| NCT01968083 |
Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children |
https://ClinicalTrials.gov/show/NCT01968083 |
Completed |
National Institute of Allergy and Infectious Diseases (NIAID) |
2015-05-31 |
| NCT00129766 |
Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children |
https://ClinicalTrials.gov/show/NCT00129766 |
Completed |
MedImmune LLC |
2006-05-31 |
| NCT00001903 |
Prevention of RSV Infections in Bone Marrow Transplant Recipients |
https://ClinicalTrials.gov/show/NCT00001903 |
Completed |
National Institutes of Health Clinical Center (CC) |
NA |